✦ LIBER ✦

Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction: Results From the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) Program

✍ Scribed by Lars G. Olsson; Karl Swedberg; Anique Ducharme; Christopher B. Granger; Eric L. Michelson; John J.V. McMurray; Margareta Puu; Salim Yusuf; Marc A. Pfeffer

Book ID: 119265854
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 431 KB
Volume: 47
Category: Article
ISSN: 1558-3597
DOI: 10.1016/j.jacc.2006.01.060

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prevention of atrial fibrillation in pat

Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program

✍ Anique Ducharme; Karl Swedberg; Marc A. Pfeffer; Alain Cohen-Solal; Christopher 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 238 KB

Reduction in all-cause mortality and mor

Reduction in all-cause mortality and morbidity with candesartan in patients with chronic heart failure and systolic left ventricular dysfunction: results of the CHARM low EF trials

✍ James B. Young; Karl Swedberg; Mark E. Dunlap; Marc A. Pfeffer; Jeffrey L. Probs 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 59 KB

The data monitoring experience in the Ca

The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program

✍ Stuart Pocock; Duolao Wang; Lars Wilhelmsen; Charles H. Hennekens 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 110 KB

Days alive and out of hospital and the p

Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program

✍ Cono A. Ariti; John G.F. Cleland; Stuart J. Pocock; Marc A. Pfeffer; Karl Swedbe 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 229 KB

Effect of candesartan on New York Heart

Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) programme

✍ E. O’Meara; S. Solomon; J. McMurray 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 36 KB

ACE Inhibitor Intolerance and Lessons Le

ACE Inhibitor Intolerance and Lessons Learned From the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Trials

✍ Domenic A. Sica 📂 Article 📅 2004 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 305 KB